Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be male and at least 18 years old
- You must have a specific genetic change in your prostate cancer cells involving the androgen receptor (a protein that helps cancer grow) — this applies to the later stage of the trial (confirm with trial site)
- Your prostate cancer must have been confirmed by a tissue sample (biopsy) and must be a specific type called adenocarcinoma, without certain aggressive features (called neuroendocrine or small cell characteristics)
- Your cancer must have spread to other parts of the body, shown by 2 or more spots on a bone scan, or visible progression on a CT or MRI scan
- Your cancer must have continued to grow after receiving at least one newer hormone-based treatment and at least one round of chemotherapy
- Any side effects from previous cancer treatments must have cleared up before joining the trial
- You must currently be receiving hormone-blocking therapy (injections to lower testosterone) or have had surgery to remove both testicles
- You must be in good enough general health to carry out daily activities with little or no limitation (confirm with trial site)
Who may not be able to join:
- People who are currently taking any other drug — whether in a trial or available to buy — that targets the same protein (androgen receptor) this trial is studying
- People who have received any other cancer treatment, including immunotherapy, chemotherapy, or radiotherapy (including certain specific treatments like lutetium, radium, or PARP inhibitors), within the 4 weeks before starting this trial
- People who have a stomach or bowel condition that affects how the body absorbs medications (for example, having had their stomach surgically removed)
- People who have serious heart or blood vessel disease
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 28 8505 8465
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidences of Protocol-defined DLT during the DLT assessment period , characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drugorally administered HP518 (Part 1); Incidence of Treatment-Emergent Adverse Events characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness; Incidence of laboratory abnormalities, characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing; Incidence of vital signs abnormalities characterized by type, frequency, severity...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.